Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

T. Karn · SciRah

Researcher profile · Semantic Scholar

T. Karn

Share profile

T. Karn — researcher profile on SciRah

h-index: 46
Works: 259
Citations: 9,757

Most-cited papers

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
C. Denkert, G. von Minckwitz, S. Darb-Esfahani, B. Lederer +23 more
2018The Lancet Oncology1,894 citations
Semantic Scholar
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
T. Karn, C. Denkert, K. Weber, U. Holtrich +20 more
2020Annals of Oncology193 citations Open access
Semantic Scholar
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
Ines Stevic, V. Müller, K. Weber, P. Fasching +12 more
2018BMC Medicine178 citations Open access
Semantic Scholar
Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis
Nandini Verma, Yaron Vinik, A. Saroha, N. Nair +8 more
2020Science Advances163 citations Open access
Semantic Scholar
Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
A. Llop-Guevara, S. Loibl, G. Villacampa, V. Vladimirova +17 more
2021Annals of Oncology80 citations Open access
Semantic Scholar
Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
A. Noske, V. Möbus, K. Weber, S. Schmatloch +15 more
2019European Journal of Cancer49 citations
Semantic Scholar
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
S. Loibl, D. Treue, J. Budczies, K. Weber +20 more
2019Clinical Cancer Research42 citations Open access
Semantic Scholar
Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
J. Furlanetto, F. Marmé, S. Seiler, C. Thode +15 more
2021European Journal of Cancer36 citations
Semantic Scholar
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
B. Sinn, K. Weber, W. Schmitt, P. Fasching +14 more
2019Breast Cancer Research36 citations Open access
Semantic Scholar
Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose dense doxorubicin/cyclophosphamide in basal-like triple negative breast cancer
K. Blenman, M. Marczyk, T. Karn, T. Qing +16 more
2022Clinical Cancer Research34 citations Open access
Semantic Scholar
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer
B. Sinn, S. Loibl, C. Hanusch, D. Zahm +18 more
2021Clinical Cancer Research34 citations
Semantic Scholar
Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial
Alexander Rüger, A. Schneeweiss, S. Seiler, H. Tesch +16 more
2020Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease33 citations Open access
Semantic Scholar
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
T. Qing, T. Karn, M. Rozenblit, J. Foldi +7 more
2022npj Breast Cancer32 citations Open access
Semantic Scholar
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs
N. Gremke, I. Besong, Alina Stroh, Luise von Wichert +17 more
2025Signal Transduction and Targeted Therapy29 citations Open access
Semantic Scholar
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
C. Massa, T. Karn, C. Denkert, A. Schneeweiss +18 more
2020Journal for ImmunoTherapy of Cancer29 citations Open access
Semantic Scholar
Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping.
C. Denkert, S. Rachakonda, T. Karn, K. Weber +36 more
2025Cancer Cell26 citations Open access
Semantic Scholar
Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer
C. Denkert, A. Schneeweiss, J. Rey, T. Karn +34 more
2024Cell Reports Medicine23 citations Open access
Semantic Scholar
Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer
V. Wali, G. Patwardhan, V. Pelekanou, T. Karn +6 more
2019Scientific Reports23 citations Open access
Semantic Scholar
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
I. Witzel, S. Loibl, R. Wirtz, P. Fasching +11 more
2019British Journal of Cancer21 citations Open access
Semantic Scholar
Catheter-related Complications of Subcutaneous Implantable Venous Access Devices in Breast Cancer Patients
A. El-Balat, I. Schmeil, T. Karn, U. Holtrich +4 more
2018In Vivo18 citations Open access
Semantic Scholar
Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging
J. Gonçalves, Christine Bollwein, A. Noske, A. Jacob +15 more
2023International Journal of Molecular Sciences16 citations Open access
Semantic Scholar
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy.
C. Denkert, M. Untch, S. Benz, A. Schneeweiss +24 more
2021Annals of Oncology16 citations Open access
Semantic Scholar
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial
M. Janning, V. Müller, E. Vettorazzi, M. Cubas-Cordova +24 more
2019International Journal of Cancer15 citations Open access
Semantic Scholar
Abstract PD2-07: mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC)– Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial
S. Loibl, B. Sinn, T. Karn, M. Untch +18 more
2019Poster Discussion Abstracts15 citations
Semantic Scholar
60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B
J. Furlanetto, F. Marmé, C. Thode, V. Nekljudova +16 more
2022Annals of Oncology12 citations Open access
Semantic Scholar
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
T. Karn, T. Meissner, K. Weber, C. Solbach +21 more
2020Clinical Cancer Research12 citations
Semantic Scholar
Quantitative analysis of the sHLA‐G protein in seminal plasma
A. Schallmoser, M. Raab, T. Karn, Sebastian Königsberger +3 more
2019American Journal of Reproductive Immunology12 citations Open access
Semantic Scholar
Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial
M. Banys-Paluchowski, S. Loibl, I. Witzel, C. Mundhenke +11 more
2019Senologie - Zeitschrift für Mammadiagnostik und -therapie12 citations Open access
Semantic Scholar
Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.
S. Loibl, B. Sinn, T. Karn, M. Untch +16 more
2019Journal of Clinical Oncology11 citations
Semantic Scholar
The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patients
F. Reimer, Sarah Bryan, K. Legler, T. Karn +11 more
2023Cancer Cell International10 citations Open access
Semantic Scholar
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy
L. Licata, Marco Barreca, B. Galbardi, M. Dugo +7 more
2023British Journal of Cancer10 citations Open access
Semantic Scholar
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
P. Jank, C. Gehlhaar, L. Bianca, Fontanella Caterina +17 more
2020PLoS ONE10 citations Open access
Semantic Scholar
RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency: post-hoc analysis of the GeparOla trial.
G. Villacampa, A. Llop-Guevara, N. Filmann, Andrea Herencia +18 more
2024Clinical Cancer Research9 citations
Semantic Scholar
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
P. Fasching, Christopher W. Szeto, C. Denkert, S. Benz +20 more
2023Clinical Cancer Research8 citations Open access
Semantic Scholar
TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary
A. El-Balat, I. Schmeil, T. Karn, S. Becker +3 more
2018Pathology and Oncology Research8 citations
Semantic Scholar
An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
P. Jank, T. Karn, M. V. van Mackelenbergh, J. Lindner +20 more
2024Clinical Cancer Research7 citations
Semantic Scholar
Impact of re-excision of residual adjacent vulvar intraepithelial neoplasia (VIN III) and histological tumour-free margin (hTFM) on survival in primary squamous cell carcinoma of vulva
K. Gasimli, Martina Straussner, I. Schmeil, T. Karn +3 more
2018Archives of Gynecology and Obstetrics7 citations
Semantic Scholar
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer
F. Conforti, V. Nekljudova, Isabella Sala, Roberto Ascari +28 more
2025Journal of Clinical Oncology6 citations
Semantic Scholar
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer
B. Sinn, K. Sychra, M. Untch, T. Karn +15 more
2024Breast Cancer Research6 citations Open access
Semantic Scholar
Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial
Terence M. Williams, A. Schneeweiss, C. Jackisch, Changxian Shen +18 more
2023Clinical Cancer Research6 citations Open access
Semantic Scholar
Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer.
T. Karn, C. Denkert, J. Rey, K. Weber +14 more
2022Journal of Clinical Oncology6 citations
Semantic Scholar
2O Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial
A. Llop-Guevara, V. Vladimirova, A. Schneeweiss, G. Villacampa +16 more
20216 citations Open access
Semantic Scholar
Biomarkers for response to immunotherapy in triple-negative breast cancer: Differences between survival and pCR biomarkers.
C. Denkert, A. Schneeweiss, J. Rey, T. Karn +16 more
2022Journal of Clinical Oncology5 citations
Semantic Scholar
Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer
L. Hanker, A. El-Balat, Z. Drosos, S. Kommoss +9 more
2021Journal of Cancer Research and Clinical Oncology5 citations Open access
Semantic Scholar
Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial.
C. Denkert, T. Link, P. Jank, M. Just +11 more
2019Journal of Clinical Oncology5 citations
Semantic Scholar
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials.
Fabio Conforti, J. Holtschmidt, V. Nekljudova, Isabella Sala +28 more
2025The Lancet Oncology4 citations
Semantic Scholar
TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer
C. Stürken, V. Möbus, K. Milde-langosch, S. Schmatloch +15 more
2021BMC Cancer4 citations Open access
Semantic Scholar
Abstract PD5-08: Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - An analysis of the GeparSepto trial
P. Fasching, C. Denkert, S. Benz, K. Weber +19 more
2020Poster Spotlight Session Abstracts4 citations
Semantic Scholar
Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.
C. Denkert, S. Rachakonda, A. Pehl, F. Marmé +33 more
2026Modern Pathology3 citations Open access
Semantic Scholar
RNA expression levels from peripheral immune cells, a minimally invasive liquid biopsy source to predict response to therapy, survival and immune-related adverse events in patients with triple negative breast cancer enrolled in the GeparNuevo trial.
H. Huebner, M. Rübner, A. Schneeweiss, C. Denkert +15 more
2023Journal of Clinical Oncology3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. V. van Mackelenbergh×30
Invite
M. V. van Mackelenbergh — researcher profile on SciRah
E. Stickeler×28
Invite
E. Stickeler — researcher profile on SciRah
S. Loibl×27
Invite
S. Loibl — researcher profile on SciRah
C. Denkert×25
Invite
C. Denkert — researcher profile on SciRah

×24

Invite

C. Schem — researcher profile on SciRah

V. Nekljudova×24

Invite

V. Nekljudova — researcher profile on SciRah

Invite

F. Marmé — researcher profile on SciRah

Invite

V. Müller — researcher profile on SciRah

P. Fasching×19

Invite

P. Fasching — researcher profile on SciRah

Invite

K. Weber — researcher profile on SciRah

A. Schneeweiss×18

Invite

A. Schneeweiss — researcher profile on SciRah

Invite

M. Untch — researcher profile on SciRah